The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming | Science Translational Medicine
Treg instability drives anti–PD-1 + anti–LAG-3 treatment efficacy and is associated with therapeutic response in patients with metastatic melanoma.
